Lopinavir-ritonavir (LPV-RTV) — Competitive Intelligence Brief

Lopinavir-ritonavir (LPV-RTV) (Lopinavir-ritonavir (LPV-RTV)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor combination. Area: Infectious Disease.

phase 3 Protease inhibitor combination HIV protease Infectious Disease Small molecule

Target snapshot

Lopinavir-ritonavir (LPV-RTV) (Lopinavir-ritonavir (LPV-RTV)) — National Institute of Allergy and Infectious Diseases (NIAID). Lopinavir-ritonavir is a combination of two protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir-ritonavir (LPV-RTV) TARGET	Lopinavir-ritonavir (LPV-RTV)	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Protease inhibitor combination	HIV protease
Darunavir/r	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
Atazanavir (Reyataz)	Atazanavir (Reyataz)	Germans Trias i Pujol Hospital	marketed	HIV protease inhibitor	HIV protease
Lopinavir and Ritonavir Tablets	Lopinavir and Ritonavir Tablets	DualityBio Inc.	marketed	HIV protease inhibitor	HIV protease
Lopinavir/r plus saquinavir	Lopinavir/r plus saquinavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	HIV protease inhibitor combination	HIV protease
ATV/r	ATV/r	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	HIV protease inhibitor (boosted)	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor combination class)

1. Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 drug in this class
2. Fundación Huésped · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. University of Chicago · 1 drug in this class